Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience.

Uday Popat, MD, Marcos J de Lima, MD, Touch Ativitavas, MD, Gabriela Rondon, MD, Leandro de Padua Silva, MD, Ebru Koca, MD, Weiqing Zhang, MD, Amin Alousi, MD, Paolo Anderlini, MD, Sergio A. Giralt, MD, Chitra M. Hosing, MD, Roy Jones, MD, PhD, Partow Kebriaei, MD, Issa Khouri, MD, Yago Nieto, MD, PhD, Muzaffar H. Qazilbash, MD, Borje S. Andersson, MD, PhD, Richard Champlin, MD

Blood (2008) 112 (11): 1131.

https://doi.org/10.1182/blood.V112.11.1131.1131

Published: 2008

Journal Articles

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.

Marcos De Lima, Leandro de Padua Silva, Sergio Giralt, Krishna Komanduri, Borje S. Andersson, Chitra Hosing, Muzaffar Qazilbash, Elizabeth Shpall, Peter Thall, Weiqing Zhang, Gloria McCormick, Xuemei Wang, Uday Popat, Andres Soriano, Amin Alousi, Richard Champlin, Guillermo Garcia-Manero

Blood (2008) 112 (11): 1134.

https://doi.org/10.1182/blood.V112.11.1134.1134

Published: 2008

Journal Articles

Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS

Gheath Alatrash, Borje S. Andersson, Matteo Pelosini, Gabrila Rondon, Muzaffar H. Qazilbash, Sergio Giralt, Leandro de Padua Silva, Chitra Hosing, Partow Kebriaei, Weiqing Zhang, Rima Saliba, Richard E. Champlin, Marcos De Lima

Blood (2008) 112 (11): 2999.

https://doi.org/10.1182/blood.V112.11.2999.2999

Published: 2008

Journal Articles

Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML

Gheath Alatrash, Matteo Pelosini, Rima M Saliba, Gabriela Rondon, Weiqing Zhang, Sergio Giralt, Partow Kebriaei, Amin Alousi, Issa F Khouri, Richard E Champlin, Marcos De Lima

Blood (2008) 112 (11): 3000.

https://doi.org/10.1182/blood.V112.11.3000.3000

Published: 2008

Journal Articles

Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.

Ri ma M. Saliba, Krishna V. Komanduri, Ebru Koca, Amin M. Alousi, Sergio Giralt, Borje S. Andersson, Weiqing Zhang, Gabriela Rondon, Uday R. Popat, Partow Kebriaei, Marcos de Lima, Richard E. Champlin

Blood (2008) 112 (11): 2227.

https://doi.org/10.1182/blood.V112.11.2227.2227

Published: 2008

Journal Articles

Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes.

Daniel Couriel, MD, Poliana Patah, MD, Rima Saliba, PhD, Lawrence Cooper, MD, Laura Worth, MD, Dimitrios Petropoulos, MD, Leandro Depadua, MD, Weiqing Zhang, Sergio Giralt, MD, Richard Champlin, MD, Elizabeth J. Shpall, MD, Marcos de Lima, MD

Blood (2007) 110 (11): 2977.

https://doi.org/10.1182/blood.V110.11.2977.2977

Published: 2007

Journal Articles

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Blood (2007) 110 (11): 1984.

https://doi.org/10.1182/blood.V110.11.1984.1984

Published: 2007

Journal Articles

The heparin-binding site of antithrombin is crucial for antiangiogenic activity

Weiqing Zhang, Richard Swanson, Gonzalo Izaguirre, Yan Xiong, Lester F. Lau, Steven T. Olson

Blood (2005) 106 (5): 1621–1628.

https://doi.org/10.1182/blood-2005-02-0547

Published: 2005

Journal Articles

Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells

Weiqing Zhang, Yung-Jen Chuang, Richard Swanson, Juan Li, Kyunga Seo, Lawrence Leung, Lester F. Lau, Steven T. Olson

Blood (2004) 103 (4): 1185–1191.

https://doi.org/10.1182/blood-2003-08-2920

Published: 2004

NARROW

Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience.

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.

Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS

Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML

Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.

Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes.

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

The heparin-binding site of antithrombin is crucial for antiangiogenic activity

Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only